Berry Genomics Co., Ltd. (000710)

Overview

Berry Genomics Co.,Ltd is a forefront player in the genomics and life science industry, primarily focused on the development and commercialization of genetic test technologies for clinical applications across China. Since its inception in 1997, the company has been leading innovations in genetic testing services, catering to a wide range of sectors including healthcare, research, and academia. Headquartered in Beijing, China, Berry Genomics extends its services to various geographical locations such as Mainland China, Hong Kong, Macao, Taiwan, Southeast Asia, the Middle East, and Australia, meeting the needs of hospitals, research institutions, universities, and enterprises with its advanced technological solutions.

Products and Services

• Non-invasive DNA Prenatal Testing Service: This service offers expectant parents a safe and effective means to gain insights into the genetic health of their unborn child, reducing the risks associated with traditional invasive testing methods.
• Genetic Disease Testing: Berry Genomics provides comprehensive genetic testing services to identify inherited diseases and conditions, helping individuals and families make informed decisions about their health and future.
• Tumor Genetic Testing: Their tumor genetic testing services play a crucial role in the detection, diagnosis, and personalized treatment plans for cancer patients, leveraging the power of genetics for better outcomes.
• NextSeq CN500 Gene Sequencer: This cutting-edge sequencer enables high-throughput genetic sequencing, supporting a wide array of genomic studies and clinical applications with remarkable accuracy and efficiency.
• Laboratory Solutions: Berry Genomics offers an array of lab solutions geared towards enhancing the operational efficiency of genetic testing facilities, including workflow optimization and advanced diagnostic tools.
• Technology Services: Their technology services span across human genome sequencing, transcriptional regulation, single cell/spatial sequencing, animal and plant genome resequencing, genome denovo sequencing, and microbial sequencing, providing a comprehensive suite of solutions for genetic research and diagnostics.
  • Human Genome Sequencing: Facilitating detailed analysis and understanding of the human genome for medical, research, and therapeutic purposes.
  • Transcriptional Regulation: Offering insights into the regulatory mechanisms of gene expression, critical for understanding disease progression and development.
  • Single Cell/Spatial Sequencing: Enabling the examination of genetic information at the single-cell level to unveil complex cellular environments and interactions.
  • Animal and Plant Genome Resequencing: Supporting genetic diversity studies and trait mapping in plants and animals, crucial for breeding and conservation efforts.
  • Genome Denovo Sequencing: Allowing for the assembly and analysis of novel genomes, providing a foundation for genetic discovery and innovation.
  • Microbial Sequencing: Facilitating the identification and characterization of microbial genomes, essential for understanding microbial functions, disease mechanisms, and biotechnological applications.
• Big Data Services: The company also leverages big data analytics to process and interpret the massive volumes of genetic information, facilitating groundbreaking research and the development of new therapies.